Stock in focus: Pharma company hits milestone with successful Phase I study of DRL_TC a tocilizumab biosimilar; get full story here!
The company offers a diverse portfolio of products and services, including APIs, generics, branded generics, biosimilars and over the counter medications.
Dr Reddy's Laboratories Ltd, a global pharmaceutical company, has been dedicated to providing affordable and innovative medicines. The company offers a diverse portfolio of products and services, including APIs, generics, branded generics, biosimilars and over-the-counter medications. With a history of scientific advancements and industry-first achievements, the company remains committed to investing in future business opportunities.
Dr Reddy's Laboratories has announced the successful completion of a Phase I study for their tocilizumab biosimilar candidate, DRL_TC. The study demonstrated pharmacokinetic equivalence, safety and immunogenicity in comparison to European Union (EU) and United States (U.S.) reference products via the intravenous route. Dr. Reddy's will now initiate a global Phase III study to further evaluate the efficacy, safety, tolerability and immunogenicity of DRL_TC compared to the reference product.
Tocilizumab, a vital anti-rheumatic medication, is utilised to treat adult patients suffering from moderate to severe active rheumatoid arthritis, specifically those who have not adequately responded to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs).
DSIJ offers a product 'Large Rhino' with recommendations for Large-Cap stocks based on research and analysis to help subscribers make informed investment decisions. If this interests you, then do download the product details pdf here
The company has delivered returns of 14.5 per cent over 3 years and excellent returns of 123.45 per cent over 5 years. With a ROCE of 26.2 per cent and ROE of 21.2 per cent, it has also achieved a 38 per cent profit CAGR over 5 years.
On Monday, during the first trading session share price of Dr Reddy’s Laboratories surged by 0.41 per cent and made an intraday high of Rs 4,652.
Investors should keep a close eye on this buzzing stock.